BAX logo

Baxter International

BAX · What the business does, what can go wrong, and how options sellers approach it

What it does

Baxter International is a medical products company that sells to hospitals, clinics and other care providers. Its products are used in everyday care: IV solutions, infusion pumps and related administration sets, injectable medicines, clinical nutrition, and surgical products such as sealants and hemostatic agents. It also sells hospital beds and patient monitoring equipment.

How it makes money

Baxter sells devices, disposables and drugs to health systems, often under long-term contracts. Many items, like IV bags and tubing, are used up and reordered, which creates repeat demand. Installed equipment such as infusion pumps can lead to repeat sales of compatible administration sets and service. Revenue comes from many countries, so currency moves can affect reported results.

Why investors own it

Hospitals need these products whatever the economic cycle, so demand tends to be steady. Installed equipment can pull through recurring sales of consumables. Some investors also see potential in operational improvement and a more focused portfolio, though that depends on execution.

What can go wrong

  • Manufacturing problems, quality issues or product recalls can interrupt supply and bring regulatory scrutiny.
  • Hospital customers are price sensitive, and large buyers have bargaining power.
  • Healthcare staffing and budget pressures can delay equipment purchases.
  • Management may miss its own financial targets or have to reset guidance.
  • Restructuring and portfolio changes can be costly and slow to pay off.
  • Debt levels matter if profits fall short.

What to watch

  • Organic sales growth by business line
  • Operating margin and gross margin trends
  • Free cash flow and debt reduction
  • Management guidance changes
  • FDA inspections, warning letters and recalls
  • Infusion pump demand and hospital capital spending
  • Supply reliability for IV solutions and injectables

Options income angle

Options on BAX are typically available across multiple expirations and are generally reasonably liquid for a large healthcare name, though activity varies by strike and date. Always check open interest and bid-ask spreads before trading.

Implied volatility tends to rise around quarterly earnings and guidance updates, and also on news about product quality, regulatory actions or supply disruptions. Premium can look attractive in those periods, but that is because the market expects bigger moves.

One caution: this stock has been known to gap sharply on earnings or guidance surprises. A covered call can cap your upside while leaving you exposed to the downside, and a cash-secured put can leave you owning shares after a large drop. Plan for that outcome before selling premium.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 12, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Baxter completed the sale of its Kidney Care business in January 2025 and used much of the proceeds to repay debt, but it still carries $9.48 billion of indebtedness. Sales grew, yet the company reported a net loss, with large impairment charges, a Novum IQ Large Volume Pump (Novum LVP) shipment hold, tariffs and a leverage target all weighing on the picture.

How the business did

  • Net sales were $11.24 billion in 2025, up 6% as reported and 3% on an "operational" basis. That non-GAAP measure strips out currency effects and Kidney Care supply-agreement sales, which alone added 3% to reported growth.
  • Net income (loss) attributable to Baxter stockholders was $(957) million, or $(1.87) per diluted share. Special items (one-off or non-core charges that management separates out) cut results by $2.09 billion. They included a $485 million goodwill impairment for the Front Line Care unit and a $290 million write-down of the Welch Allyn trade name.
  • Advanced Surgery sales rose 9% and Drug Compounding rose 10%. Infusion Therapies & Technologies was flat ($4,101 million versus $4,103 million) because of the Novum LVP hold and weaker U.S. IV solutions demand. Injectables and Anesthesia fell 2%. Pharmaceuticals segment operating income was $222 million versus $313 million.
  • The gross margin ratio was 30.1% versus 37.5%. Cash flow from continuing operations was $951 million, against capital expenditures of $513 million and dividends of $348 million. Interest expense, net fell to $238 million from $341 million after debt repayments.
  • The company repaid $3.81 billion of legacy debt and a further $2.00 billion using proceeds from new notes.

Risks specific to this company

  • Debt and credit ratings: The company says it has yet to hit its net leverage targets and could miss the end-of-2026 goal. In the fourth quarter of 2025 S&P cut its senior debt rating to BBB- and Moody's cut it to Baa3. Further downgrades could raise borrowing costs. The quarterly dividend was cut to $0.01 per share.
  • Novum LVP recalls: The FDA classified the pump corrections as Class I recalls, its most serious category. Shipments and installations in the U.S. and Canada are on hold with no release date, and the company expects no meaningful Novum LVP sales meanwhile. It recorded roughly $105 million of related charges.
  • Hurricane Helene aftermath: Damage to the North Cove plant is repaired, but customers adopted fluid conservation practices that management expects to keep IV solutions demand lower.
  • Tariffs and sole-source suppliers: Results have been hurt by tariffs and are expected to keep being hurt. Reliance on single suppliers limits the company's ability to switch inputs.
  • IRS examination: The IRS is reviewing transfer pricing with the company's Costa Rica and Puerto Rico manufacturing operations for 2019 and 2020. Reserves are approximately $280 million, and a larger assessment could be material.
  • More impairments possible: Front Line Care goodwill was $1.52 billion at year-end. A hypothetical 5% drop in its fair value would cause an additional impairment of approximately $160 million.

What management is watching

  • Reaching its net leverage target. A November 2025 amendment raised the maximum net leverage ratio allowed under the revolving credit facility through the quarter ending September 30, 2026. The company could draw approximately $1.79 billion under it at year-end.
  • Offsetting the "dis-synergies" and stranded costs left by the Kidney Care sale, meaning overhead no longer shared with that business. Restructuring continues, and transition-services income was a main part of the $206 million of other operating income.
  • The timing of the Novum LVP hold release, which management calls uncertain. The Spectrum IQ pump remains available as an alternative.
  • Spending: R&D was $518 million, and capital spending is aimed at capacity expansion, production efficiency and quality systems.
  • The FDA reclassified the Claris Ahmedabad site as VAI (acceptable compliance) on October 31, 2025. Management expects the 2023 Warning Letter to be closed.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Baxter reported third-quarter net income attributable to stockholders of $294 million, or $0.57 per diluted share, compared with $(46) million a year earlier. A $253 million gain on early extinguishment of debt (paying off debt before its due date) helped the result. Sales grew 5%, while the FDA issued a Warning Letter on the Round Lake sterile injectables plant and the Novum LVP pump shipment hold remained in place.

How the business did

  • Sales: Third-quarter net sales were $2,976 million versus $2,835 million, up 5% at actual rates and on an organic basis. For nine months, sales were $8,637 million, up 4% (3% organic).
  • Segments: Under a new two-segment structure, Medical Products & Therapies sales rose 6%. Within it, Advanced Surgery rose 12% to $342 million on hemostats and sealants, and Infusion Therapies & Platforms rose 5% to $1,760 million, helped by the Spectrum IQ pump. Healthcare Systems & Technologies sales rose 4% to $806 million.
  • Profit: Operating income was $225 million versus $172 million. The gross margin ratio was 33.4% versus 33.5%. Excluding special items, it fell 1.1 percentage points on unfavorable product mix and a lower contribution from pricing. Special items cut net income by $5 million, compared with $401 million a year earlier.
  • Nine-month profit: Net income attributable to stockholders was $405 million, or $0.78 per diluted share, versus $171 million. Second-quarter tariff refunds of approximately $75 million were recorded in cost of goods sold.
  • Cash and capital: Operating cash flow from continuing operations for nine months was $1.07 billion versus $355 million, helped by lower inventory and better collections. Capital expenditures were $363 million and debt repayments were $600 million. The company bought back no shares and had approximately $1.30 billion left on its authorization. It held $1.98 billion of cash.

What management is watching

  • Novum LVP: The temporary stop on distributing and installing the pump in the U.S. and Canada continues, and the timing of its release is uncertain. Management expects no meaningful Novum LVP sales while the holds last. Spectrum IQ remains the alternative.
  • Round Lake: The FDA issued a Warning Letter in September 2026 after an inspection of the Illinois plant. The company responded in October 2026 and is carrying out corrective actions.
  • Costs and trade: Management expects results to be adversely affected by Section 122 duties and Section 301 tariffs. It is also working on cost savings to offset losses from the Kidney Care sale. Business optimization charges were $61 million in the quarter.
  • Balance sheet and impairment: An August 2026 amendment raised the maximum net leverage ratio allowed under the credit facility for five quarters. S&P and Moody's moved their outlook to Negative in the first quarter. Management is also monitoring Front Line Care goodwill of $1.51 billion and the Welch Allyn trade name at $390 million for possible write-downs.
  • Measure to know: Organic sales growth is a non-GAAP measure (not defined by standard accounting rules) that strips out currency swings, acquisitions and divestitures, and Kidney Care supply agreement sales.

Follow BAX in Kortex

The Kortex app shows BAX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.